Neopharma Technologies - Investor Relations

ABOUT NEOPHARMA TECHNOLOGIES, LTD.

Neopharma Technologies Ltd is an Australian public company that participates in the multi-billion-dollar, global Point-of-Care (POC) health testing market.

Neopharma aims to be a leader in this market with its AI Empowered NEOVAULT® digital testing platform, revolutionizing the rapid POC industry. This cutting-edge technology combines artificial intelligence, cognitive assessment tools, and comprehensive data analysis to transform diagnostic testing across multiple sectors. By addressing critical challenges in workplace safety, healthcare, and beyond, the company’s NEOVAULT® platform is poised to become integral technology servicing the $6B US Drugs-of-Abuse (DOA) testing market.

Our company’s mission is to become the global default testing platform within this industry and to expand NEOVAULT® reader and platform into the broader healthcare diagnostic industry.

We’ve completed the R&D phase of the company’s growth and have just entered our commercialization phase with a clearly defined path to a NASDAQ listing.

As part of this growth path, last year Neopharma appointed US DOA industry leader Nina French as the company’s US based CEO.

Neopharma Technologies intends to list on to a US OTC exchange as a first step towards a subsequent NASDAQ listing after the commercialization and global roll out of its NEOVAULT® digital drug and impairment testing platform this year, given that most of the company's revenue will be derived from the USA which is the world's largest drugs-of-abuse testing market.

In the US alone there are about 250 million drug tests done annually. These are predominantly paper based with recording, record-keeping and reporting all performed and stored manually. The NEOVAULT® Solution digitizes these workflows. With 52 million of these being done by laboratories that have a 4–7-day turnaround on test results, the rest being POC rapid tests in the field that take collectors up to half an hour to perform the test and compile a test report.

Our NEOVAULT® solution produces an AI generated test report within minutes saving time and money. NEOVAULT® enabling many drug testing kits from many manufacturers to be paired with the NEOVAULT® platform via a unique QR code printed onto each test kit.

Neopharma’s global growth strategy includes partnering with the largest manufacturers of drug test kits that already have sales of millions of test kits annually.

Neopharma’s commercialization involves charging a fee for any drug test report (up to $2 USD) and impairment subscriptions (up to $10 USD/employee/month) and individual impairment test reports (up to $10 USD) originating from each individual QR code, with a rebate going back to the manufacturer. This creates a new revenue stream for our partnered manufacturers whilst Neopharma benefits from accessing their significant global sales networks.

Neopharma is currently preparing for the enablement of the first 5 million drug test kits, with a weighted pipeline of over 100 million QR codes (and growing) over the next few years.

Funds raised from this investment offer will be utilized to expand the company’s IT & Implementation teams to help scale up the roll out of NEOVAULT® to realize the company’s current $58M USD of pipeline revenue opportunities across 33 companies currently in 2025.

Neopharma Technologies welcomes your participation in this investment offer at this exciting time in the company's growth and look forward to providing regular updates to our shareholders as we achieve significant milestones this year.

LEADERSHIP TEAM

MARCUS L'ESTRANGE

EXECUTIVE CHAIRMAN

Marcus is an Engineer who has extensive experience in the IT Industry, the Mining Industry, the Oil and Gas Industry, and the Environmental Industry. He has been involved with the start-up of several successful companies within these sectors. He has a diverse range of skills as an engineer as well as in sales and marketing and business development. Marcus is the Managing Director of Raptor Global Corporation Ltd, an Australian public company with an Australian Financial Services License (AFSL) that provides corporate services to assist companies to grow globally. Marcus was also previously the Chairman of Cirralto, an ASX listed IT company.

SHAUN MELVILLE

EXECUTIVE DIRECTOR

Shaun Melville has a wide range of experience in Sales and Marketing across industries of IT, Health, Mining, and Financial Services. Shaun has a Bachelor’s degree in Psychology. Shaun recently completed his Oxford Executive Leadership Course with a final overall result of 93.7%. Shaun is currently an Executive Director of Raptor Global Corporation Ltd, an Australian public company with an Australian Financial Services License (AFSL) that provides corporate services to assist companies to grow globally.

NINA M FRENCH

CHIEF EXECUTIVE OFFICER

Nina M. French has more than 30 years of experience in the employee screening industry and a deep understanding of drug testing program design, policies, state laws, federal regulations, product development and supporting technologies. In addition to executive leadership roles both at one of the largest Third-Party Administrators in the industry and at two product innovation firms, Nina has served as the President of DATIA and as an industry advisor to TPAs and CRAs across the country at her prior consulting firm.

Nina frequently speaks at conferences and regularly contributes to the thought leadership of the drug and alcohol testing industry. She is widely published and is featured on podcasts, interviews and publications in safety, drug testing, and human resources.

GAJENDDRA RAJ

CHIEF TECHNOLOGY OFFICER

Gajenddra is an entrepreneurial-spirited, pioneering technologist with executive-level experience identifying, qualifying, building, implementing, and enabling technologies and enterprise systems that facilitate business processes and strategic objectives. Skilled in all phases of the software development lifecycle; expert in translating business requirements into technical solutions; with a focus on quality, usability, security, and scalability. Broad expertise in IT, infrastructure, and security with architecture/ infrastructure design, full project life cycle management, and operational management.

Gajenddra has been the Chief Technology Officer for Neopharma Technologies Ltd since the inception of the company in June 2017. He has driven and managed the development of NEOVAULT® and is the principal technical liaison officer with NTL’s international clients.